Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enlivex Therapeutics Ltd.

1.22
+0.130011.93%
Post-market: 1.240.0200+1.64%19:54 EDT
Volume:236.81K
Turnover:287.44K
Market Cap:26.83M
PE:-1.26
High:1.29
Open:1.14
Low:1.12
Close:1.09
Loading ...

Company Profile

Company Name:
Enlivex Therapeutics Ltd.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
14 Einstein Street,Ness Ziona,Israel
Zip Code:
7403618
Fax:
972 2 670 8070
Introduction:
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Directors

Name
Position
Shai Novik
Chairman of the Board
Abraham Havron
Director
Baruch Halpert
Director
Bernhard Kirschbaum
Director
Gili Hart
Director
Hyun Gyu Lee
Director
Michel Habib
Director
Sangwoo Lee
Director

Shareholders

Name
Position
Oren Hershkovits
Chief Executive Officer
Shachar Shlosberger
Chief Financial Officer
Dror Mevorach
Chief Scientific and Medical Officer